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Abstract
In the last decades, few mechanistically novel therapeutic agents have been developed to treat mental and
neurodegenerative disorders. Numerous studies suggest that targeting BDNF and its TrkB receptor could be a promising
therapeutic strategy for the treatment of brain disorders. However, the development of potent small ligands for the TrkB
receptor has proven to be difficult. By using a peptidomimetic approach, we developed a highly potent and selective TrkB
inhibitor, cyclotraxin-B, capable of altering TrkB-dependent molecular and physiological processes such as synaptic
plasticity, neuronal differentiation and BDNF-induced neurotoxicity. Cyclotraxin-B allosterically alters the conformation of
TrkB, which leads to the inhibition of both BDNF-dependent and -independent (basal) activities. Finally, systemic
administration of cyclotraxin-B to mice results in TrkB inhibition in the brain with specific anxiolytic-like behavioral effects
and no antidepressant-like activity. This study demonstrates that cyclotraxin-B might not only be a powerful tool to
investigate the role of BDNF and TrkB in physiology and pathology, but also represents a lead compound for the
development of new therapeutic strategies to treat brain disorders.
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Introduction
Brain-Derived Neurotrophic Factor (BDNF) belongs to the
neurotrophin family that regulates neuronal development and
survival by interacting with two classes of cell surface receptors,
TrkB receptor and the non-selective p75
NTR receptor [1]. Binding
of BDNF to TrkB triggers receptor dimerization and subsequent
autophosphorylation on tyrosine residues. In addition, TrkB
receptors can be activated in absence of BDNF either through
spontaneous dimerizations or through different signal transduction
systems, including dopamine, adenosine, Pituitary Adenylate
Cyclase-Activating Polypeptides (PACAP), endocannabinoids,
glucocorticoids or the inorganic ion Zinc [2,3,4,5,6,7]. Although
BDNF was initially considered to be involved in the development
and maintenance of central and peripheral nervous systems, more
recent evidence have implicated BDNF in the regulation of
synaptic strength and long-term memory processes [8].
Given its trophic effects on neurons and its central role in high-
order cognitive functions, BDNF has rapidly emerged as a key
element in the pathophysiology of numerous brain disorders,
including neurological disorders [e.g. epileptogenesis [9]], neuro-
degenerative diseases [e.g. amyotrophic lateral sclerosis [10],
Huntington [11], Alzheimer’s and Parkinson’s diseases [12]] and
psychiatric disorders [e.g. anxiety/depression [13,14], addiction
[15] and schizophrenic psychosis [16]]. Altogether, these obser-
vations present BDNF and TrkB as a promising new therapeutic
target. However, due to the lack of specific modulators, the
behavioral consequences of a systemic intervention on the BDNF/
TrkB system in these pathologies and in high-order cognitive
functions still remain elusive.
Since no structural data are available for the BDNF/TrkB
complex, the development of specific ligands has been difficult to
address. Moreover, the large surface of the putative binding
domain for BDNF makes the design of small molecules more
complex. Numerous studies have implicated the solvent-exposed
loops of BDNF in mediating their biological effects. Site-directed
mutagenesis analyses, production of chimeric neurotrophins and
mimetic peptides have highlighted specific and variable regions
among neurotrophins that are important for the binding specificity
and/or activation of their cognate Trk receptors [for reviews, see
[17,18,19]]. Moreover, other groups have designed functionally
active peptidomimetics of neurotrophins [see examples in
[20,21,22,23,24,25,26,27]], demonstrating the feasibility of this
strategy. Therefore, to develop a potent TrkB ligand active in vivo,
we took advantage of these seminal studies and we designed
several BDNF-derived mimetic peptides, which were tested for
their ability to modulate the activity of the human TrkB receptor.
Here, we describe the properties of a small inhibitor peptide
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9777mimicking the reverse turn structure of the variable region III that
protrudes from the core of BDNF, which we named cyclotraxin-B.
Results
Strategy for the design of cyclotraxin-B
To design small modulators of the TrkB receptor, we used a
strategy that rapidly produces and isolates mimetic peptides by
direct proteolysis of mature BDNF. Among several proteases,
endoproteinase Glu-C V8 appeared best suited at producing
sequences of interest distributed along the BDNF sequence (Fig. 1
and Table 1). Proteolytic fragments were purified and identified
using a HPLC system connected to a mass spectrometer. Since the
main purpose of this study was to develop modulators active on
human TrkB receptor, fragments were then assessed in presence of
BDNF on the human TrkB receptor, which was expressed in
CHO cells in an inducible-manner (TetOn-rhTrkB). For that
purpose, we developed a modified version of the previously
described KIRA-ELISA [28], a rapid, sensitive and high-capacity
assay that quantifies TrkB activation in ELISA microtiter plates by
measuring phosphorylation of its tyrosine residues [see Data S1
and Fig. S1,S2]. Four fractions were found to significantly
decrease BDNF-induced TrkB activity (Fig. 1C), including
Fragment #(05), corresponding to region III. This fragment was
of major interest compared to others because of its very low
molecular weight (,1,200 Da) and highly specific sequence in
BDNF. We therefore used both sequence and structure of region
III as a basis for the design of cyclotraxin-B, which has been
cyclized via terminal cysteine residues to mimic the native
structure of this region in BDNF (See Fig. 2A).
Cyclotraxin-B binds TrkB and alters both basal and BDNF-
induced activity with high potency
In a first set of experiments, cyclotraxin-B was assayed on
human TrkB receptors using the recombinant TetOn-rhTrkB
system. Cyclotraxin-B was found to inhibit BDNF-induced TrkB
activity through a non-competitive mechanism with a high
potency (IC50=0.3060.07 nM; Fig. 2B,D). When compared to
peptide L2-8, a BDNF-mimetic peptide previously described by
others [22], cyclotraxin-B proved to have a potency three-order of
magnitude higher, in KIRA-ELISA (L2-8 IC50=108663 nM;
Fig. 2B,D). Binding of [
125I]-BDNF was not altered by
cyclotraxin-B (Fig. S3), suggesting further that cyclotraxin-B is
an allosteric modulator of the receptor by acting through TrkB
binding sites that are not critical for the interaction with BDNF
but rather involved in its activation capacity. This hypothesis was
further confirmed by binding studies using biotinylated cyclo-
traxin-B. In fact, to test whether cyclotraxin-B is able to interact
with TrkB, we performed histochemical staining using a
biotinylated version of the peptide on slices issued from either
control or transgenic mice lacking the TrkB receptor in the
forebrain. This transgenic mouse line was created by breeding
CamKIIa-CRE mice [29] to floxed TrkB homozygous mice [30].
The resulting CamKIIa-CRE TrkB flox/flox mice were then
crossed to TrkB flox/flox mice to generate 50% CamKIIa-CRE
TrkB flox/flox mice (mutants) and 50% TrkB flox/flox mice
(control littermates). Because of the selectivity of the expression of
CRE recombinase using the CamKIIa promoter, the TrkB gene is
only inactivated in the forebrain. As shown in Figure 3, whereas
cyclotraxin-B is detected in different structures of the forebrain of
control mice (e.g. dorsal striatum, cortex or hippocampus), no or
very weak staining was observed in the same regions of conditional
TrkB knockout mice. These observations are comparable to the
staining obtained in parallel with a selective TrkB antibody.
Together, these results demonstrate that cyclotraxin-B selectively
interacts with TrkB without altering the binding of BDNF.
The pharmacological properties of cyclotraxin-B were then
tested in native conditions, using primary cultures of mouse
cortical neurons. Contrary to TetOn-rhTrkB cells, cortical neurons
naturally express TrkB receptors and its co-receptor, p75
NTR.
p75
NTR is known to alter TrkB conformation and provide greater
discrimination for its cognate ligand, BDNF [1], as illustrated by
the difference in both affinity and activity observed between
BDNF and NT-3 in neurons but not in TetOn-rhTrkB cells (Figs.
S2 and S3). Accordingly, when cyclotraxin-B was tested on native
TrkB receptors in cortical neurons, both amplitude of inhibition
and potency were enhanced with a 1.6-fold greater inhibition
(256.768.8% in neurons vs. 234.866.4% in TetOn-rhTrkB cells)
and a one-order of magnitude higher potency than that observed
in TetOn-rhTrkB cells (IC50=67.1618.9 pM), while still remain-
ing non-competitive (Fig. 2C,E and Fig. S3). Analysis of the
reversibility of the inhibitory effects elicited by cyclotraxin-B also
demonstrated kinetics differences between TetOn-rhTrkB cells and
neurons. The tK of cyclotraxin-B was ,3 hours in TetOn-rhTrkB
cells and ,6 hours in neurons (Fig. 2F,G), both demonstrating
long-lasting effects of cyclotraxin-B after its withdrawal. These
relative high values may reflect the high affinity of cyclotraxin-B
for recombinant and native TrkB. Similarly, the significant
difference in tK may be explained by the difference in potencies
observed between the two cell types.
Contrary to L2-8, cyclotraxin-B also decreased a BDNF-
independent (basal) TrkB activity in both recombinant cells and
neurons with the same relative inhibition as in presence of BDNF
(TetOn-rhTrkB cells, 232.568.0% and IC50=0.2860.08 nM;
neurons, 253.065.8% and IC50=65.7621.7 pM; Fig. 2B-E).
Endogenously synthesized BDNF was not involved in this
apparent basal activity since neutralizing anti-BDNF antibody
did not alter cyclotraxin-B effects (Fig. S4A) and no BDNF was
detectable by ELISA. This spontaneous activity may result from
transactivations by G-protein coupled receptors (GPCR) [2,3],
zinc [5], endocannabinoids [6] but also from increases in receptor
density that lead to spontaneous autophosphorylation [31]. This
basal activation of TrkB may selectively occur in densely packed
area throughout soma, dendrites and axons, at the plasma
membrane but also in intracellular vesicles [32,33]. Taking
advantage of the inducible heterologous TetOn-rhTrkB system,
we investigated the effect of cyclotraxin-B at different TrkB
densities. As expected, a threshold in TrkB expression was needed
to detect a basal TrkB activity (Fig. S4B) and the relative
inhibition of cyclotraxin-B was stable at all TrkB densities, either
in presence or in absence of BDNF (Fig. 4A). In cortical neurons,
it has been shown that glucorticoids such as dexamethasone can
indirectly activate TrkB receptors [7]. As shown in Figure 4B,
dexamethasone significantly triggered TrkB phosphorylation in
our cortical neurons cultures. This activation via glucorticoids
signaling pathways was fully prevented by cyclotraxin-B, contrary
to a functional anti-TrkB antibody capable of inhibiting BDNF-
dependent TrkB activity only. These results suggest that not only
cyclotraxin-B blocks the effects of BDNF on TrkB but also any
direct or indirect processes capable of activating TrkB.
Cyclotraxin-B alters TrkB-related physiological and
pathophysiological cellular events
We next extended the evaluation of the functions of cyclotraxin-
B to TrkB-regulated cellular processes. BDNF is known to
promote neurite outgrowth, notably in nnr5 PC12-TrkB cells,
through MAP-Kinase (MAPK) signaling pathway activation.
Addition of BDNF to TrkB/p75
NTR co-expressing nnr5 PC12-
TrkB Inhibitor Active In Vivo
PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9777Figure 1. Purification and identification of binding determinants of BDNF. (A) Alignment of the amino-acid sequences of rat BDNF, NT-4/5,
NT-3 and NGF (numbered based on BDNF sequence, dashes represent gaps, points represent identities and stars represent strongly similar amino
acids). Variable regions are boxed and labeled (Loops L1, L2, L3 and L4). (inset) Three-dimensional structure of a BDNF monomer (PDB entry, 1bnd).
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branch points (Fig. 5A). The BDNF-induced neurite outgrowth
was dose-dependently prevented by cyclotraxin-B with similar
pharmacological properties to that of cortical neurons in KIRA-
ELISA assays (249.360.5%; IC50=12.268.5 pM) (Fig. 5A,B).
Application of cyclotraxin-B to nnr5 PC12-TrkB cells dramatically
decreased the BDNF-induced phosphorylation of MAPK, pro-
portionally to its effect on neurite outgrowth (Fig. 5C). Note that
neither spontaneous neurite outgrowth nor basal phospho-MAPK
levels could be detected in absence of BDNF, so that no
cyclotraxin-B effect could be assessed in this experimental
condition. Cyclotraxin-B was selective to TrkB receptors since
concentrations up to 1 mM did not affect NGF- nor NT-3-induced
neurite outgrowth in nnr5 PC12-TrkA and -TrkC, respectively
(Fig. 5D). Moreover, morphological analysis ruled out toxicity
effects of cyclotraxin-B and no cell death was observed even
72 hours after exposure to 10 mM cyclotraxin-B.
Reports have proposed that a sustained activation of
TrkB receptors by BDNF or through GPCR transactivations
could lead to enhanced neuronal vulnerability to toxic insults
[10,34,35,36,37]. Although the underlying mechanisms are poorly
known, studies performed on cultured cortical neurons have
shown that excess BDNF can induce neuronal death through
activation of TrkB but not p75
NTR [34,37]. In this context, we
tested the effect of cyclotraxin-B in a model of BDNF-induced
neuronal necrosis. While repeated exposure to high concentrations
of BDNF induced cortical neurons necrosis, treatment with
cyclotraxin-B fully prevented BDNF-induced cell death without
altering normal neuron survival (Fig. 5E). These results
demonstrate the neuroprotective effects of cyclotraxin-B in this
experimental paradigm. Similar conclusions were drawn from cell
survival experiments using MTT (methylthiazolyldiphenyl-tetra-
zolium bromide) method (Fig. S5).
BDNF and TrkB also play a central role in the long-term
modulation of synaptic plasticity [8]. We thus tested cyclotraxin-B
on BDNF-induced protein synthesis in neurons, a process that is
linked to induction and maintenance of the late events of long-
term potentiation (LTP). As shown in Figure 5F, the BDNF-
induced increase in newly synthesized protein level was signifi-
cantly reduced by cyclotraxin-B. Of interest is the decrease in
basal rate of protein synthesis by cyclotraxin-B, which reproduced
half of the inhibition induced by the non-selective Trk inhibitor
K252a. This suggests that a part of basal rate of protein synthesis
depends on basal TrkB activity in neurons. Neither BDNF nor
cyclotraxin-B showed any effect on non-induced TetOn-rhTrkB
cells (data not shown). The phosphorylation of the eukaryotic
initiation factor 4E (eIF4E) is known to underlie the TrkB-
dependent protein synthesis that occurs during synaptic modula-
tion by BDNF, as shown in Figure 5F (see also Fig. S6).
Cyclotraxin-B significantly reduced the level of phosphorylated
eIF4E protein both in the absence and in the presence of the
neurotrophin. Remarkably, these effects were linearly correlated
to those observed on protein synthesis, thus suggesting a direct link
between these two cellular events and TrkB modulation. Since
LTP at the Schaffer collateral-CA1 synapses is known to require
BDNF derived from presynaptic CA3 neurons [29], attempts were
made to determine whether cyclotraxin-B was able to affect
tetanus-induced LTP in this neural network. As shown in
Figure 6A, while HFS applied to hippocampal slices induced
LTP in both control and cyclotraxin-B-treated slices (169615%,
P,0.001, and 13466%, P,0.01, respectively; 50–60 min after
HFS), this potentiation was significantly decreased in presence of
cyclotraxin-B (P,0.01, 50–60 min after HFS). As previously
observed by Kang and colleagues using function-blocking TrkB
antiserum [38], cyclotraxin-B did not alter either synaptic strength
or presynaptic functions (Fig. 6B,C). These results indicate that
Table 1.
Fragment Corresponding region m/z [M+H]+ (+Cys-CAM)
a Position Peptide sequence
#(01) N-Terminus 1024.6 1–9 HSDPARRGE
(-)
#(02) - 952.04 10–18 LSVCDSISE
(1009.45)
#(03) Loop L1 2279.59 19–40 WVTAADKKTAVDMSGGTVTVLE
(-)
#(04) Loop L2 1814.11 41–55 KVPVSKGQLKQYFYE
(-)
#(05) Region III 1271.47 56–66 TKCNPMGYTKE
(1328.59)
#(06) Loop L4 6220.31 67–119 GCRGIDKRHWNSQCRTTQSYVR
+ C-Terminus (6485.32) ALTMDSKKRIGWRFIRIDTSCVCTLTIKRGR
aAll cysteine residues have been treated with iodoacetamide to form carbamidomethyl-cysteine (Cys-CAM)
doi:10.1371/journal.pone.0009777.t001
Isolation of these regions by endoproteinase Glu-C V8 (black arrows) resulted in the production of six fragments (#(01) to #(06)). (B) Fragments were
purified by HPLC using a non-linear gradient (dashed line) and identified by ESI-MS (solid line). All expected fragments and fragments resulting from
miscleavage of BDNF were found. Only the four fragments capable of inhibiting the BDNF-induced TrkB activity in (C) are noted. (C) Representative
KIRA-ELISA inhibition profile of 80 HPLC fractions. Fractions (,0.3 mM final) were assayed in the presence of 1 nM BDNF. Most fractions did not
produce significant inhibitions (#) except four fractions (N single fragments, m miscleavage fragments). Mean 6 s.e.m. of values obtained in
triplicate in 8 independent experiments are noted in brackets.
doi:10.1371/journal.pone.0009777.g001
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normal synaptic transmission at Schaffer collateral-CA1 synapses.
Altogether, these results demonstrate that cyclotraxin-B alters
signaling pathways associated to both BDNF-induced and basal
TrkB activities, in normal and/or deleterious conditions.
Systemic injections of cyclotraxin-B to mice result in TrkB
inhibition in the brain and alters anxiety-related behavior
The overall purpose of the present study was to develop a TrkB
modulator that can be administered by systemic injection and then
to assess the resulting behavioral central effects. In order to allow
its delivery to the brain after intravenous injections, we fused the
non-toxic transduction domain of the tat protein from the HIV
type 1 [39] to cyclotraxin-B (tat-cyclotraxin-B). KIRA-ELISA
showed that the fusion with tat did not alter the pharmacological
properties of cyclotraxin-B (Fig. S7). In contrast, the fusion with
tat even enhanced the efficacy of cyclotraxin-B to inhibit TrkB in
brain slices (cyclotraxin-B, 229.865.6%, n=9; tat-cyclotraxin-B,
251.263.6%, n=12; P,0.05), while tat-empty (a tat peptide
lacking the cyclotraxin-B sequence) did not produce any effect.
This enhancement may reflect the plasma membrane permeability
of the tat-fused cyclotraxin-B that facilitates its penetration into the
slice and/or targeting of intracellular active TrkB receptors. We
then treated adult mice with tat-cyclotraxin-B or tat-empty
following a double-injection procedure (see protocol in Fig. S8).
Four hours after the last intravenous injection, tat-cyclotraxin-B
was detected in many brain structures that normally express TrkB
(cortex, hippocampus, striatum, nucleus accumbens; Fig 7A),
demonstrating the stability of the compound in vivo. More
interestingly, the total level of TrkB phosphorylation in tat-
cyclotraxin-B-treated mice was dramatically decreased as com-
pared to saline or tat-empty-treated animals (Fig. 7B). Similar
results were obtained amongst all these brain regions (not
illustrated). Western blot analysis using phospho(Y816)-TrkB
antibody showed comparable effects with a reduction of
37.764.7% in band intensity (Fig. S8B), suggesting that
cyclotraxin-B inhibits both PLCc and Shc binding sites.
Remarkably, even with very different administration kinetics
(minutes for incubation; hours for injection), the decrease in TrkB
activity was not significantly different when tat-cyclotraxin-B was
injected to animals or directly added to the slice (injection,
50.963.1%; slice incubation, 52.063.9%; Fig. 7B). This latter
observation thus illustrates the long-lasting effects of tat-cyclo-
traxin-B in vivo.
BDNF and TrkB have been shown to regulate develop-
ment of depression-like phenotypes and anxiety-related behaviors
[14,40,41,42], depicting TrkB as a promising target for the
development of new therapeutic compounds [13,43]. In this
context, we focused the study of adult mice injected with tat-
cyclotraxin-B on depression-like and anxiety-like behaviors. First,
mice were subjected to the forced swim test (FST), a test that is
commonly used for its predictive validity regarding antidepressant
compounds. In this test, tat-cyclotraxin-B was compared to
paroxetine, a well-characterized antidepressant compound. As
for many antidepressant compounds, mice acutely treated with
paroxetine demonstrated significant decreased time of immobility
and increased climbing attempts (Fig. 7C). This escape behavior
was not observed for mice that received saline solution or tat-
cyclotraxin-B, suggesting that cyclotraxin-B does not possess any
antidepressant-like properties when injected acutely. Noteworthy,
swimming capabilities were not affected in mice treated with tat-
cyclotraxin-B, suggesting no locomotor alterations. In a second set
of experiments, tat-cyclotraxin-B was assessed for its potential
anxiolytic-like properties. Treated mice were tested in the open
field and in the elevated-plus maze (EPM), two tests used for their
predictive validity regarding anxiolytic compounds. In the open
field, mice injected with tat-cyclotraxin-B did not show any
alterations in locomotor activity, confirming our previous
observations (Fig. 7D). Moreover, tat-cyclotraxin-B-injected mice
spent significantly more time in the center compartment compared
to saline controls, suggesting anxiolytic effects of the compound.
To confirm this putative anxiolytic property, effects of acute
treatment with tat-cyclotraxin-B were then assessed using EPM
and compared to diazepam, a benzodiazepine commonly used to
treat anxiety in humans. Remarkably, mice that received tat-
cyclotraxin-B exhibited an anxiolytic profile similar to that of
diazepam. In fact, both compounds significantly increased the
number of entries and the time spent in open arms with
comparable amplitude of effects (Fig. 7E). Overall, these
behavioral studies further demonstrated the specificity of central
effects elicited by tat-cyclotraxin-B after intravenous injections and
confirmed its pharmacological potential in vivo, for its use in animal
models of brain disorders.
Discussion
Since the discovery of the first antidepressant and antipsychotic
medications fifty years ago, few novel therapeutic agents have been
developed for the treatment of psychiatric diseases. Most of the
time, new treatments are based on improving existing treatment
strategies rather than targeting new molecular pathways. There is
an increasing literature that proposes TrkB receptor signaling as a
promising target for the treatment of psychiatric disorders
[13,14,15,16], but also epilepsy [9], neurodegenerative diseases
[10,11,44], and even cancer [45]. In consequence, as the first
potent and specific modulator of TrkB receptors that can be easily
administered in vivo, cyclotraxin-B opens new avenues for
therapeutic interventions.
The proposed involvement of BDNF or TrkB in diseases is
mostly based on an excess or a lack of the BDNF/TrkB coupling
that was measured either in human post-mortem tissue or in
Figure 2. Cyclotraxin-B is a highly potent allosteric inhibitor of TrkB receptor with long-lasting effects. (A) Design of cyclotraxin-B. (Left)
Sequence alignment of the four neurotrophins on the highly variable region III (gray box). The two cysteine residues used for cyclization are in red.
Point, conserved residues; asterisk, highly similar residues. (Right) 3-D structure of a BDNF monomer (adapted from PDB entry 1bnd) and sequence of
cyclotraxin-B. Variable regions are indicated and higher magnification of region III is boxed. The position of the disulfide bond is shown as a dashed
line. (B-E) Characterization of TrkB inhibition by cyclotraxin-B using KIRA-ELISA assays in TetOn-rhTrkB cells (B,C) and in cortical neurons (D,E). (B,D)
Increasing concentrations of cyclotraxin-B (B, n=6;D, n=5) or L2-8 (n=3) were added to the cells with or without BDNF. (C,E) BDNF concentration-
response experiments with or without cyclotraxin-B (C,1mM, n=6;E, 100 nM, n=6). Addition of cyclotraxin-B resulted in a significant uncompetitive
antagonism (C,F 1,285=88.0, P,0.0001; E,F 1,279=199.9, P,0.0001) and did not change BDNF EC50 (C, BDNF 672692 pM, + cyclotraxin-B 749691 pM;
E, BDNF 186650 pM, + cyclotraxin-B 178652 pM), as shown by Eadie-Hofstee plotting of the data (insets). Results are expressed as the ratio
between phospho- and total-TrkB in percentage of basal value. Data are mean 6 s.e.m. (triplicates, n=6), except for insets where data are mean. (F)
Slow reversibility of cyclotraxin-B inhibition in TetOn-rhTrkB cells and in cultured neurons. After 30-min exposure to cyclotraxin-B, cells were rapidly
washed and incubated in KIRA-ELISA medium for increasing times before the addition of BDNF. Data are mean 6 s.e.m. (triplicates, n=4) and are
expressed in percentage of inhibition. (G) Means 6 s.e.m. of half times obtained in (F). * P=0.02.
doi:10.1371/journal.pone.0009777.g002
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not always coherent, especially for those regarding psychiatric
diseases, such as schizophrenic psychoses for instance [16].
Therefore, it will be difficult to predict the effect of a modulator
of TrkB activity in such cases. Cyclotraxin-B represents a great
tool to evaluate the consequences of systemic pharmacological
interventions on TrkB receptors in pathologies with altered
BDNF/TrkB signaling. An example of such consequences is
Figure 3. Cyclotraxin-B interacts with TrkB. Fixed slices from adult
control and transgenic CamKIIa-CRE x TrkB flox/flox (TrkB-CRE) mice
were incubated overnight with biotinylated cyclotraxin-B or anti-TrkB
antibody. Regions of the forebrain in which the expression of TrkB is
knocked out in the transgenic mice are shown (Left to right: dentate
gyrus of hippocampus, prefrontal cortex, dorsal striatum; 406
magnification). Data presented for biotinylated cyclotraxin-B are those
obtained with 0.1 mM of but are similar with concentrations up to 1 mM.
Scale bar, 200 mm.
doi:10.1371/journal.pone.0009777.g003
Figure 4. Cyclotraxin-B inhibits both BDNF-dependent and -
independent TrkB activity. (A) Cyclotraxin-B inhibition of density-
related TrkB activity. Cells were induced with doxycycline (see Fig. S4B)
and were treated with BDNF (4 nM), cyclotraxin-B (1 mM) and K252a
(1 mM) before KIRA-ELISA analysis (N BDNF, # BDNF+cyclotraxin-B, m
basal, D cyclotraxin-B, & K252a, % K252a+cyclotraxin-B). Inset shows
amplitude of inhibition of BDNF-induced and basal activities. Data are
mean 6 s.e.m. (triplicates, n=3). Results are expressed in percentage of
values obtained in non-induced cells. (B) Cyclotraxin-B inhibition of
glucocorticoid-dependent TrkB activity in neurons. Cortical neurons
were treated with control medium, dexamethasone (1 mM, 2 h) or BDNF
(4 nM), in presence or not of cyclotraxin-B (1 mM) or a monoclonal anti-
TrkB antibody (30 mg/ml). Data are mean 6 s.e.m. (triplicates, n=6) and
are expressed in percentage of basal values; ** P,0.01, *** P,0.001,
compared to basal/control condition; 111 P,0.001, compared to
dexamethasone alone; ### P,0.001, compared to BDNF condition.
doi:10.1371/journal.pone.0009777.g004
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PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9777shown here: global targeting of brain TrkB receptors by
intravenous injections of cyclotraxin-B has effects on anxiety-
but not depression-related behaviors. Our observations are in line
with two recent studies demonstrating that mice susceptible to
stress-related disorders after chronic social defeat have an
overactivity of BDNF/TrkB signaling in their reward system
[40,41]. This suggests that acute systemic interventions using
cyclotraxin-B may preferentially act on the reward system in the
brain, resulting at the behavioral level in anxiolytic-like activities
rather than on the stress axis and its antidepressive effects [13].
Such specificity in the behavioral effects of cyclotraxin-B may be
explained by its capacity to alter the basal activity of TrkB
receptors. Brain regions that possess a high basal activation level
will thus be more sensitive to cyclotraxin-B. Our results are also
consistent with previous studies using transgenic mice lacking
TrkB receptors for which no alteration in depressive-like behaviors
could be observed [46,47]. In addition, the anxiolytic- but not
antidepressant-like profile may reflect the difference in the kinetics
of treatment for both conditions, with acute effects for anxiolytic
compounds versus chronic effects for antidepressant molecules.
Overall, this study gives a first insight to the predictive
pharmacological class of cyclotraxin-B, which appears to behave
as an anxiolytic drug similar to other benzodiazepines rather than
as an antidepressant compound.
The sustained effect elicited by cyclotraxin-B after transient
application both in vitro and in vivo is a result of the high affinity and
slow reversibility of the interaction with the receptor. It may also
be due to its small size that reduces protease-sensitivity. However,
long-term treatments with TrkB modulators may have unexpected
consequences on receptor internalization and recycling. In fact,
such modulation may alter the plasma membrane-bound TrkB
receptor level, making it difficult to predict the long-term effects of
cyclotraxin-B. As well, cyclotraxin-B proved to behave differen-
tially on TrkB if p75
NTR is co-expressed or not. Numerous reports
demonstrated that the functional cooperation between p75
NTR
and Trk receptors is responsible for a better discrimination in
binding for a specific neurotrophin and higher amplitude of
response. In a same way, in presence of p75
NTR, cyclotraxin-B,
like BDNF, gains in binding affinity, amplitude of inhibition and
kinetics of action. It has been proposed that coexpression of
p75
NTR and Trk receptors may induce receptors aggregation in
lipid rafts, convergence of signaling pathways or recruitments of
different intracellular adaptors [48,49]. Since cells in the central
nervous system express TrkB alone or together with p75
NTR, one
can expect differential amplitude of effects of cyclotraxin-B
depending on the targeted region. As a partial allosteric inhibitor,
cyclotraxin-B should avoid the deleterious effects of a full inhibitor.
Indeed, BDNF and its receptor have important trophic and
protective effects on neuronal cells so that a minimal level of TrkB
activity must be preserved, which is warranted if cyclotraxin-B is to
be used therapeutically. Moreover, it is noteworthy that under
some circumstances BDNF promotes cell death. For instance,
reports have demonstrated that necrosis of cultured cortical
neurons can be induced by BDNF, a process abolished by
inhibiting TrkB with antisense oligonucleotides or K252a [34] and
absent in cultures made from cortices of TrkB-null mice [35].
Therefore, in conditions in which hyperactivity of the BDNF/
TrkB system increases the vulnerability of neurons to excitotoxic
insults [10,34,35,36], cyclotraxin-B can be used as a neuroprotec-
tive agent by maintaining the receptors in a minimal active state.
Pharmacological studies performed with KIRA-ELISA demon-
strate that cyclotraxin-B not only blocks the effects of BDNF on
TrkB but also any direct or indirect processes capable of activating
TrkB (e.g. spontaneous dimerization or glucocorticoids, respec-
tively). Therefore, cyclotraxin-B may allosterically interfere with
TrkB optimal conformation, thereby preventing its proper
activation, independently of the mechanism of activation (Fig. 8).
This specific property makes cyclotraxin-B a great tool for
investigating TrkB transactivation mechanisms as well as sponta-
neous TrkB dimerizations in physiology and pathology. TrkB
transactivation processes have been linked to crucial physiological
events such as synaptic plasticity [5], neuron migration and
morphogenesis [6] and neuroprotection [7]. In addition, basal
more than BDNF-dependent TrkB activity may play a critical role
in the etiology of some pathologies such as epileptogenesis [9],
amyotrophic lateral sclerosis [10] and cancer metastases [50]. An
example of the importance of the basal TrkB activity in physiology
as revealed by cyclotraxin-B is reported in Figure 6. Surprisingly,
the effect on the LTP reduction appeared high (from about 170 to
135%) relative to the partial inhibition of cyclotraxin-B. In
comparison, Korte et al. have reported a reduction within the same
range, from about 190% to 135%, using BDNF knockout mice
[51]. This high effect could be due to the fact that TrkB inhibition
is more general since cyclotraxin-B inhibits not only the effect of
BDNF on TrkB but also the basal TrkB activation. These results
suggest an important component of the BDNF-independent
activity of TrkB receptors in the regulation of synaptic plasticity,
as proposed by others [5]. Finally, cyclotraxin-B inhibits the two
main signaling pathways downstream TrkB with similar amplitude
of effects. In fact, activation of TrkB triggers the phosphorylation
of two Tyrosine residues that form binding sites for Shc (Y515) and
PLCc (Y816). KIRA-ELISA assays performed with a pan-
phospho-tyrosine antibody first demonstrated that cyclotraxin-B
inhibits the overall phosphorylation level of TrkB. Then, we
showed that cyclotraxin-B inhibits the activation of the MAPK
pathway as well as subsequent neurite outgrowth, two signaling
downstream the binding of protein Shc to phosphorylated Y515.
Finally, western blots performed with a specific phospho(Y816)-
TrkB antibody demonstrated that cyclotraxin-B also inhibits the
activation of the PLCc binding site and subsequent processes such
Figure 5. Cyclotraxin-B inhibits normal and deleterious cellular signaling events associated with TrkB but not TrkA nor TrkC. (A-D)
Cyclotraxin-B inhibits TrkB- but not TrkA- nor TrkC-dependent neurite outgrowth. (A) Representative photomicrographs of nnr5 PC12-TrkB cells
treated for 48 h with cyclotraxin-B and/or BDNF. 206magnification. (B) Quantitative analysis of BDNF-induced neurite outgrowth in presence of
increasing concentrations of cyclotraxin-B. Data are mean 6 s.e.m. (sixplicates; n=5). (C) Quantitative analysis and representative western blot of
total and phospho-MAPK in nnr5 PC12-TrkB cells treated as indicated. Data are mean 6 s.e.m. (n=4) and are expressed in percentage of basal
condition; *** P,0.001 compared to control; 111 P,0.001, compared to BDNF. (D) nnr5 PC12-TrkA and -TrkC cells were incubated with cyclotraxin-B
(1 mM) in presence or not of NGF or NT-3, respectively. (E) Cyclotraxin-B prevents BDNF-induced neurons death. Cortical neurons were treated with
cyclotraxin-B or BDNF, as described in methods. Data are mean 6 s.e.m. (sixplicates, n=5) expressed in percentage of control. *** P,0.001 compared
to control; 111 P,0.001, compared to BDNF. (F) Cyclotraxin-B inhibits cap-dependent protein translation in cortical neurons. [
35S]-methionine
incorporation into proteins (white bars) was measured in cortical neurons exposed to cyclotraxin-B, K252a and BDNF, as indicated. Phosphorylation of
eIF4E was quantified by immunoblots (black bars). Data are mean 6 s.e.m. (triplicates, n=5) and are expressed in percentage of basal condition; *
P,0.05, ** P,0.01, *** P,0.001, compared to respective basal condition; 1 P,0.05, 11 P,0.01, compared to respective BDNF condition. Inset shows
correlations between TrkB-dependent protein synthesis and eIF4E phosphorylation. (1) K252a, (2) cyclotraxin-B, (3) basal, (4) BDNF + cyclotraxin-B, (5)
BDNF.
doi:10.1371/journal.pone.0009777.g005
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cyclotraxin-B is able to inhibit the two active sites of TrkB (p-
Y816/PLCc and p-Y515/Shc) as well as downstream processes
associated to these pathways (Shc/MAPK/neurite outgrowth and
PLCc/synaptic plasticity).
Altogether, these observations suggest that cyclotraxin-B
represents a promising tool for the study of the BDNF/TrkB
signaling in pathological and physiological processes and could
serve as a lead compound for the development of novel
therapeutic strategies.
Figure 6. Cyclotraxin-B impairs HFS-induced LTP without affecting basal synaptic transmission. (A) Effect of prior exposure to
cyclotraxin-B on tetanus-induced LTP in the CA1 area. Grouped recordings are shown before and after tetanic stimulation (arrow) for control and
cyclotraxin-B-treated hippocampal slices. Representative fEPSPs recorded 5 min before (a) and 60 min after (b) LTP induction are shown. Results are
expressed in percentage of baseline response and are the mean 6 s.e.m. (n=829 slices). (B) Input-output curves plotting of fEPSP slopes against
presynaptic fiber volley (PSFV) slope in control (r
2=0.84; n=7) and cyclotraxin-B-treated slices (r
2=0.92; n=10). Individual traces obtained for control
and cyclotraxin-B-treated slices are shown. (C) Scatter plot depicting the facilitation ratio obtained in control (n=7) and cyclotraxin-B-treated slices
(n=10). Mean 6 s.e.m. is indicated by the large symbol with the error bars while smaller symbols represent data obtained in each experiment.
Representative sweeps obtained with control and cyclotraxin-B-treated slices are shown.
doi:10.1371/journal.pone.0009777.g006
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Ethics statement
All experimental procedures were carried out in accordance
with the INSERM committee guidelines and European Commu-
nities Council Directive (86/609/EEC, 24 November 1986)
regarding the care and use of animals.
Plasmid constructs and cell lines
Plasmid constructs were generated by using standard cloning
techniques and were confirmed by sequencing. The human
recombinant TrkB receptor was fluorescently tagged at its C-
terminus with the Enhanced cyan fluorescent protein (rhTrkB-
ECFP) by cloning the full human TrkB sequence [52] (kindly
provided by G. M. Brodeur) into the pECFP-N1 expression vector
(Clontech). For inducible expression, rhTrkB-ECFP was subcloned
into the tetracycline-responsive (TetOn) vector pTRE2 (Clontech).
Chinese Hamster Ovary cells stably expressing rhTrkB-ECFP
(TetOn-rhTrkB cells), were produced by transfection of the
pTRE2-rhTrkB-ECFP plasmid into CHO-K1 TetOn cells (Clon-
tech) followed by clone selection in 0.25 mg/ml hygromycin B
(Invitrogen) and 0.1 mg/ml geneticin (G418; Invitrogen). Resis-
tant cells were selected based on both fluorescence intensity and
KIRA-ELISA profile after an overnight incubation in presence of
1000 ng/ml doxycycline (Clontech). Cortical neurons were
prepared and cultured from E16 mouse embryos as described
previously [53]. The nnr5 PC12-TrkA, nnr5 PC12-TrkB and nnr5
PC12-TrkC cells (kindly provided by M. V. Chao) are NGF non-
responding mutant PC12 cells stably transfected with TrkA, TrkB
and TrkC cDNA, respectively [54].
Figure 8. Proposed mechanism of cyclotraxin-B inhibition depending on TrkB activation state. (1) Inactive receptor monomer, (2) BDNF-
induced activation, (3) High density-induced activation. (4) Src kinase-mediated transactivation. Cyclotraxin-B binds to TrkB sites different from those
of BDNF and induces a less-active transconformation state of the receptor, as schematized by the shape of activation loops and the number of
phosphorylated residues (circled P, global phosphorylation level) on the intracellular kinase domain. This results in a decrease in activation of TrkB
downstream signaling cascades, as schematized by the size of descending arrows.
doi:10.1371/journal.pone.0009777.g008
Figure 7. Cyclotraxin-B is active in vivo after systemic injections and demonstrates anxiolytic-like but not antidepressant-like
effects. (A) Brain localization of biotinylated tat-cyclotraxin-B after intravenous injections. Cx, cortex; St, striatum; NAc, Nucleus Accumbens;
Hip, hippocampus. (B) KIRA-ELISA analysis of brain TrkB receptors from mice treated with saline (sal), tat-empty (empty) or tat-cyclotraxin-B
(cyclo) as described in Figure S8. Results are expressed in percentage of control condition. Data are mean 6 s.e.m. (sixplicates, n=18from6
mice). *** P,0.001, compared to saline. (C) No antidepressant-like action of tat-cyclotraxin-B. Mice treated with saline solution (n=11), tat-
cyclotraxin-B (n=6)orparoxetine(n=8) were tested for anti-depressive behaviors using FST. Results are mean 6 s.e.m. ** P,0.01, compared to
saline. (D) Anxiolytic-like effect of tat-cyclotraxin-B with no effect on locomotor activity in the open field. Mice treated with either saline (n=10)
or tat-cyclotraxin-B (n=10) were subjected to an open field. (Up) The total distance traveled in the periphery and in the center was measured
during 30 min. (Inset) Cumulative distance measured during the 30-min trial does not show any locomotor alterations. (Down) The normalized
distance traveled in the bright center is expressed as a ratio between the distance traveled in the center and the total distance. For the
normalized distance in center, there was a significant effect of treatment (F1,108=0.337,P,0.001) and time (F5,108=0.068, P=0.01).Resultsare
mean 6 s.e.m. (E) Anxiolytic-like effect of tat-cyclotraxin-B comparable to that of diazepam. Mice that received saline solution (n=7), tat-
cyclotraxin-B (n=10) or diazepam (n=7) were assessed for anxiety-like behaviors in the EPM procedure. Data are expressed as a ratio between
e n t r i e si no p e na r m so v e rt o t a ln u m b e ro fe n t r i e sa n dr a t i o between time in center over total time. Results are mean 6 s.e.m. * P,0.05, **
P,0.01, compared to saline.
doi:10.1371/journal.pone.0009777.g007
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characterization of fragments
Ten micrograms (0.37 nmoles) of mature recombinant human
BDNF (Peprotech) were dissolved in 400 mM ammonium
bicarbonate buffer (pH 8.0) and cysteine bridges were reduced
by adding 10 mM DTT for 15 min at 50uC and alkylated by
15 mM iodoacetamide for 15 min at room temperature. Digestion
buffer was diluted to 100 mM ammonium bicarbonate buffer
before adding endoproteinase Glu-C (type V8; Sigma) in a 1:100
(enzyme:protein) ratio for 24 h at 37uC. Digestion mixture was
dried, reconstituted in 50 ml water and divided in two samples.
The first sample (10 ml, ,74 pmole) was used for the separation
and identification of fragments using Liquid Chromatography/
ElectroSpray Ionization-Mass Spectrometry (LC/ESI-MS). Mass
spectra were acquired on a LCQ Advantage ion trap mass
spectrometer (Thermo Electron). On-line HPLC separation
of the fragments was accomplished with an Atlantis column
(2.16150 mm, Waters) packed with dC18 adsorbent (5 mM,
300 A ˚) (mobile phase A, 0.1% formic acid; mobile phase B,
80% acetonitrile, 0.1% formic acid). The first 2.5 min at 0%
mobile phase B were derivatized to waste. The following non-
linear gradient was then used: 0–15% B over 4.5 min, 15–30% B
over 23 min, 30–50% B over 10 min, 50–100% B over 2 min,
100% B over 3 min, 100-0% B over 1 min (flow rate: 250 ml/min).
The column was washed within 4 min with 100% solvent B before
reequilibration with mobile phase A. Digestion fragments were
sequentially fragmented into the ion trap by collision-induced
dissociation using an isolation width of 2 and a relative collision
energy of 35%. Mass spectrometry and mass spectrometry
fragmentation data allowed an unambiguous identification of the
different fragments using predictive m/z and the Bioworks
software. The second sample (,30 ml) was used for separation
and isolation of fragments into aliquots. Using exactly the same
HPLC parameters than previously, we saw to it that one fragment
was distributed in only one fraction and reciprocally, that one
fraction contained only one fragment at a time. Fractions were
dried, washed two times, reconstituted in 50 ml water and stored at
-20uC. Fractions (,1 mM final) were then tested in competition
with BDNF (20 ng/ml) using KIRA-ELISA. Four distinct BDNF
digestions reproducing the same LC/ESI-MS profile were
performed. Each fraction was tested in triplicate in six different
KIRA-ELISA assays.
Peptides design and synthesis
See SI for methods for the production of mimetic peptides.
Cyclotraxin-B, L2-8, tat-cyclotraxin-B and tat-empty were
purchased from BioS&T. Peptide sequences were as fol-
lows: cyclotraxin-B, CNPMGYTKEGC( cyclized by disulfide
bridge); L2-8, CVPVSKGQLC [22]; tat-cyclotraxin-B, YGRK-
KRRQRRRCNPMGYTKEGC; biotinylated tat-cyclotraxin-B,
Biotin-YGRKKRRQRRRCNPMGYTKEGC; tat-empty, YGR-
KKRRQRRR. Peptides were purified to the highest grade by
reverse-phase HPLC (.98.5%).
KIRA-ELISA
TrkB activity was quantified using the previously described
KIRA-ELISA assay [28] with slight modifications. Cortical
neurons were seeded on polyornithin-coated flat-bottom 96-well
culture plates (12610
4 cells per well) and cultured eight days at
37uCi n5 %C O 2. TetOn-rhTrkB cells were seeded on flat-bottom
96-well culture plates (4610
4 cells per well) and incubated
overnight with 1000 ng/ml doxycycline (Figs. S1,S2) except
when indicated. Fluorescence levels in TetOn-rhTrkB cells were
verified before each assay. Both cell types were carefully washed
four times with Dulbecco’s modified Eagle’s medium (DMEM,
Invitrogen) before being pre-treated for 30 min with ligands and
stimulated for 20 min with 4 nM BDNF, except when indicated in
the figures, in DMEM containing 0.5% BSA and 25 mM Hepes
(pH 7.4). Assay was stopped by removing the medium on ice and
membranes were solubilized using KIRA-ELISA solubilization
buffer (NaCl 150 mM, Hepes 50 mM, Triton X-100 0.5%,
thimerosal 0.01%, sodium orthovanadate 2 mM, supplemented
with a cocktail of protease inhibitors) for 1 h at room temperature.
Solubilized membranes were transferred for 2 h at room
temperature onto ELISA microtiter plate (Nunc Maxisorp) pre-
coated overnight at 4uC with appropriate antibodies [polyclonal
anti-GFP (1:5000, Clontech) for TetOn-rhTrkB, polyclonal anti-
TrkB (1 mg/ml, Upstate) for cultured neurons and brain slices, for
phosphorylation assays; monoclonal anti-GFP (1:3000, Chemicon)
for TetOn-rhTrkB, monoclonal anti-TrkB (1:1000, BD Bioscienc-
es) for cultured neurons and brain slices, for total TrkB
quantification]. Tyrosine phosphorylation was revealed by a 2 h
incubation with biotinylated anti-phosphotyrosine (4G10, 0.5 mg/
ml; Upstate) and a streptavidin-peroxydase system (1:4000;
Amersham Biosciences). Total TrkB was revealed by a 2 h
incubation with polyclonal anti-GFP (1:5000, Clontech) for
TetOn-rhTrkB, or polyclonal anti-TrkB (1 mg/ml, Upstate) for
cultured neurons and brain slices, followed by appropriate
secondary antibodies and a peroxydase system. Absorbance was
read at 450 nm after addition of 3,39,59,5-tetramethyl-benzidine
substrate (Sigma) and acidification with 1N hydrochloric acid.
Background signal was defined as indicated in Fig. S2.
BDNF quantification
Endogenous BDNF was quantified in cortical neuron cultures
by using the BDNF Emax immunoassay system (Promega).
Fluorescence
ECFP fluorescence quantification was read at 485 nm using a
Mithras LB 940 counter (Berthold Technologies).
[
125I]-BDNF binding studies
Two micrograms of recombinant human BDNF (Peprotech)
were dissolved in 50 mM phosphate buffer (pH 7.0). Iodination
was allowed by incubation with 0.5 mCi [
125I] and chloramine T
and reaction was stopped by addition of sodium disulfite. The
labeled BDNF was purified by PD-10 desalting columns
(Amersham Biosciences) and fractions containing the [
125I]-BDNF
were pooled (63.3 mCi/mg). Competition binding studies were
done mainly as previously described [55]. Briefly, 2.523610
5 cells
or neurons were carefully washed with ice-cold binding buffer
(DMEM containing 0.5% BSA and 25 mM Hepes) before being
treated as indicated in the figures. Cells were then washed four
times with ice-cold binding buffer and lyzed with 1N NaOH.
Radioactivity was counted in a 1260 MultiGammaII counter
(LKB Wallac).
Immunoblot analysis
Cell lysates were prepared in boiling SDS (2%, w/v) as
described previously [56] and subjected to SDS-PAGE. Detection
and analysis of eIF4E, MAPK and Akt phosphorylation were done
using anti-total and -phospho-eIF4E antibodies (1:1000, Cell
Signaling), anti-total and -phospho-MAPK antibodies (1:1000,
Cell Signaling) or anti-total and–phospho (Ser473) Akt antibodies
(1:1000, Santa Cruz; 1:1000, Cell Signaling, respectively),
respectively. For TrkB expression analysis, cortical neurons were
TrkB Inhibitor Active In Vivo
PLoS ONE | www.plosone.org 13 March 2010 | Volume 5 | Issue 3 | e9777cultured for eight days and TetOn-rhTrkB cells were incubated
overnight with doxycycline. Cells were solubilized as for KIRA-
ELISA assays and lysates were centrifuged at 14,0006g for 20 min
at 4uC. Cleared supernatant was collected and proteins were
subjected to SDS-PAGE. Detection of rhTrkB-ECFP and
neuronal mouse TrkB were performed using anti-GFP polyclonal
antibody (1:5000, Clontech) and anti-rodent TrkB polyclonal
antibody (1 mg/ml, Upstate), respectively. TrkB phosphorylation
was quantified using anti-phospho-TrkB antibody (kindly provided
by M.V. Chao) [57]. Proteins were visualized using appropriate
HRP-conjugated secondary antibodies and films were quantified
by densitometry.
Immunofluorescence
Cortical neurons seeded on polyornithin-coated cover slips were
fixed in 4% paraformaldehyde for 20 min and washed in glycine
buffer (0.1 M, pH 7.4). Detection was performed using anti-rodent
TrkB polyclonal antibody (1 mg/ml, Upstate) or anti-rodent MAP-
2 monoclonal antibody (1:500, Millipore) in Saponine buffer
(0.05%) supplemented with 0.2% BSA and 10% heat-inactivated
fetal bovine serum and revealed using Alexa488-conjugated
(1:100, Interchim) or Cy3-conjugated (1:200, Jackson) appropriate
secondary antibodies.
Immunohistochemistry
Mice were injected twice with 200 mg of biotinylated tat-
cyclotraxin-B. Three hours after the first injection, animals were
deeply anesthetized with pentobarbital and perfused intracardia-
cally with a solution of saline followed by 4% paraformaldehyde.
Brains were postfixed for 1 h in 4% paraformaldehyde and cut in
40-mm sections with a vibratome. Sections obtained at the same
levels as for in vivo KIRA-ELISA analysis (see Fig. S8) were rinsed
in PBS and incubated in TBS containing 0.05% Tween-20 with
VectaStain ABC Elite kit (Vector Laboratories). Signal was
revealed using 3,39 diaminobenzidine (DAB). Non-injected mice
were used as negative controls for endogenous biotin.
Histochemistry using biotinylated cyclotraxin-B
Control and CamKIIa-Cre TrkB fl/fl adult mice (see below)
.12 weeks-old were transcardially perfused with 4% paraformal-
dehyde. Brains were post-fixed overnight in 4% PFA, cryopre-
served in 30% sucrose and cryosectioned into 40 mm sagittal
sections. Sections were stored in PBS with azide. Biotinylated
cyclotraxin-B was incubated at 0.1 or 1 mM overnight at 4uC.
Sections were rinsed in PBS and signal was revealed using
VectaStain ABC Elite kit (Vector Laboratories). Signal was
revealed using 3,39 diaminobenzidine (DAB). In parallel, adjacent
sections were blocked in normal mouse serum and incubated with
monoclonal mouse anti-TrkB (1:250; BD Bioscience) overnight at
4uC. Signal was revealed as for biotinylated cyclotraxin-B. In both
conditions (biotinylated cyclotraxin-B and anti-TrkB), a slight
staining could be sometimes observed for some slices (only at 1 mM
for cyclotraxin-B). This signal is consistent with other studies using
the similar transgenic mice [30] and may be attributed to TrkB-
expressing glial cells and/or a not total knockout.
Neurite outgrowth assessment
nnr5 PC12 cells were prepared as described elsewhere [58].
nnr5 PC12-TrkB, -TrkA and -TrkC cells were treated with
cyclotraxin-B (100 nM) and BDNF (1 nM), NGF (2 nM) or NT-3
(10 nM), respectively. The number of cells bearing neurites longer
than 2 cells in diameter was microscopically determined in each
counting field (two fields per well, three wells per condition).
Counting was performed blind each 24 h for three days. Data
presented in the figures are those obtained for 48 h but are similar
at 24 h and 72 h.
Metabolic labeling with [
35S]-methionine
Measurement of [
35S]-methionine incorporation was mainly
performed as described previously [56] Cortical neurons were
washed twice and incubated with DMEM containing 0.5% BSA
and 25 mM Hepes for 5–6 h. Neurons were incubated for 20 min
with 4 nM BDNF in the presence of 4 mCi/ml of [
35S]-methionine
(1000 Ci/mmol, Amersham Biosciences). Cyclotraxin-B (100 nM)
and K252a (10 mM) were added for 30 min prior to BDNF (4 nM)
stimulation. Neurons were washed twice and protein were
precipitated with trichloroacetic acid (TCA; 10%, w/v). Amino
acid uptake into neurons and incorporation into proteins were
estimated by counting the radioactivity in the supernatant and the
pellet, respectively. [
35S]-Methionine incorporation was calculated
as the ratio of TCA-precipitable to TCA-soluble radioactivity.
None of the treatments altered [
35S]-methionine uptake into
neurons.
Assessment of cell injury
Neurotoxicity experiments were performed on cortical neurons
(25610
4 cells per well in 24-well plates) cultured in presence of
glial cells in Neurobasal medium supplemented with B27 (Gibco)
for 10–14 days. Mature cultures were then washed carefully and
serum-free medium containing cyclotraxin-B (200 nM) or BDNF
(4 nM), alone or in combination, was added to the cells each 24 h
for 72 h. Neuronal necrosis was determined by measuring the
leakage of LDH with respect to total LDH using the kit of Sigma,
as described by the manufacturer. Necrosis was estimated as a
function of LDH released compared to total LDH. Cell survival
was quantified by measuring the reduction of MTT into a blue
formazan precipitate that is subsequently solubilized in dimethyl
sulphoxide and read at 560 nm.
Animals
Adult male Sprague-Dawley rats and Swiss mice (2–3 months-
old and 4–6 weeks, respectively; Janvier) were used. Forebrain-
specific TrkB transgenic mice (CamKIIa-Cre TrkB fl/fl mice) used
for biotinylated cyclotraxin-B histochemistry have been created by
breeding CamKIIa-Cre mice [29] to floxed TrkB homozygotes
mice [30] to generate CamKIIa-Cre+ TrkB fl/wt mice and then
crossed to TrkB fl/fl mice to generate CamKIIa-Cre TrkB fl/fl
mice. The resulting line had low neonatal survival but surviving
animals matured unremarkably. Animals were maintained on a
controlled light-dark cycle at a constant temperature (2262uC)
with ad libitum access to food and water.
Electrophysiological recordings
Hippocampal slices (400 mm) were prepared as previously
described [59]. Cyclotraxin-B was directly diluted in medium
(1 mM) and slices were incubated for at least 30 min. Slices
were then transferred to a submersion-type recording chamber
equilibrated with 95% O2,5 %C O 2, and submerged in a stream of
medium containing 1 mM cyclotraxin-B for ,20 min prior to I/O
curves and PPF recordings or to LTP induction (see below).
Extracellular recordings were performed at room temperature in
apical dendritic layers of CA1 area using glass micropipettes filled
with 2 M NaCl with a resistance of 2–6 MV. Field excitatory
postsynaptic potentials (fEPSPs) were evoked by electrical
stimulation of CA1 afferent Schaffer collaterals and commissural
fibers in the stratum radiatum. Test stimuli (100 ms duration) were
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15 seconds.
Long-term potentiation (LTP). LTP was induced by
applying high frequency stimulation (HFS) to Schaffer collaterals
(two 1-sec trains at 100 Hz separated by 20 seconds) after baseline
recording (at least 15 minutes or until stable). The magnitude of
fEPSPs was determined by measuring the slope of fEPSPs. Three
successive fEPSPs were averaged (each fEPSP was normalized to
the mean of fEPSPs recorded before tetanus) and plotted across
time using Pclamp9 software (DIPSI). Recording after single pulse
testing was performed for at least 60 minutes following tetanus.
Input/Output (I/O). Curves were constructed to assess the
responsiveness of AMPA/Kainate glutamate receptor subtypes-
dependent responses to electrical stimulation in slices. Slopes of
three averaged presynaptic fibre volleys (PFVs) and fEPSPs were
plotted as a function of stimulation intensity (400–2200 mA).
Paired-pulse facilitation (PPF). PPF of synaptic
transmission induced by paired-pulse stimulation was monitored
at 40 ms inter-stimulus intervals. PPF was quantified by
normalizing the slope of the second fEPSP by the slope of the
first one.
Intravenous delivery of cyclotraxin-B and in vivo KIRA-
ELISA analysis
Adult Swiss mice (20–25 g) received a double 90-min-interval
i.v. injection of saline buffer, tat-cyclotraxin-B (26200 mg) or tat-
empty (26200 mg). Three hours after the first injection, mice were
decapitated, brains quickly removed on ice, 300-mm coronal
sections were prepared with a vibratome at three levels (bregma
0.90 mm: caudate putamen/nucleus accumbens level; bregma
21.60 mm: dorsal hippocampus level; bregma 22.70 mm:
ventral hippocampus level, see SI Fig. 8A) and placed in a
holding chamber for one hour. Slices were then incubated in
Ringer’s solution supplemented with tat-cyclotraxin-B or tat-empty
(1 mM) in holding chamber saturated with 95% O2,5 %C O 2.
After 45 min incubation, BDNF (4 nM) was added for 20 min.
Experiments were stopped by quick removing of the medium on
ice. Slices were homogenized in KIRA-ELISA solubilization
buffer (NaCl 150 mM, Hepes 50 mM, Triton X-100 0.5%,
thimerosal 0.01%, sodium orthovanadate 2 mM, supplemented
with a cocktail of protease inhibitors) and membranes were left
solubilized overnight at 4uC. Protein concentrations were
determined and equal amounts of proteins were loaded in each
well for KIRA-ELISA assays (see above). The following antibodies
combination was used for phosphorylation assays: TrkB capture
with polyclonal anti-TrkB (1 mg/ml); tyrosine phosphorylation
quantification with biotinylated anti-phosphotyrosine (4G10,
0.5 mg/ml) and a streptavidin-peroxydase system (1:4000). The
following combination was used for total TrkB quantification:
TrkB capture with monoclonal anti-TrkB (1:1000); total TrkB
quantification with polyclonal anti-TrkB (1 mg/ml). Absorbance at
450 nm was read after addition of TMB and acidification.
Behavioral testing
Mice were treated as described above before being subjected to
behavioral studies. Predictive estimation for anxiolytic properties
of tat-cyclotraxin-B was assessed using open field and elevated
plus-maze (EPM). Antidepressant-like action of tat-cyclotraxin-B
was assessed with the forced-swim test (FST). Effects of acute
treatment with tat-cyclotraxin-B on spontaneous locomotion,
exploration and reactivity to a novel open field was assessed in
plexiglas activity chambers (Med Associates; 45645631 cm). Mice
were placed into the center of the open field, and activity was
recorded for 30 min. Testing took place under bright ambient
light conditions to increase the anxiety component of the center
areas of the field (defined as the central 15615 cm portion). Mice
subjected to EPM received a double 90-interval i.v. injection of tat-
cyclotraxin-B or saline buffer before being placed on the platform
of the EPM and assessed for 5 min (2665636 cm). The diazepam
control group consisted of saline buffer double-treated mice that
further received a 30-min i.p. injection of diazepam (1 mg/kg).
Mice were assessed for number of entries and amount of time
spent in open versus closed arms. The FST procedure was applied
to treated mice as described by Porsolt et al. (see ref. [60]). Mice
were dropped individually into glass cylinder (height, 25 cm;
diameter, 10 cm) containing 10 cm water height, maintained at
23–25uC. Animals were tested for a total of 6 min. The total time
of swimming, the number of climbing attempts and the time of
immobility was recorded during the last 4 min of the session, after
2 min of habituation. The paroxetine control group consisted of
saline buffer double-treated mice that further received a 30-min
i.p. injection of paroxetine (2 mg/kg). Behaviors were recorded on
videotape and scored blind.
Statistical analysis
Concentration-response and competition curves were obtained
using an iterative least-squares method derived from that of Parker
& Waud (1971). Eadie-Hofstee plotting of the data provided
estimates for BDNF EC50 in presence or not of cyclotraxin-B and
IC50 values of peptides L2-8, cyclotraxin-B and tat-cyclotraxin-B.
KIRA-ELISA competition studies, protein synthesis, eIF4E
phosphorylation, HFS-induced LTP and survival assessments
(MTT and LDH release methods) were analyzed using one-way
ANOVA followed by Newmann-Keuls multiple comparison post-
hoc test. Concentration-response curves and Eadie-Hofstee plots
were analyzed using two-way ANOVA. Significance over time in
locomotor activity studies was given using two-way ANOVA
followed by Bonferroni’s post-hoc test. Cyclotraxin-B reversibility
and 30-min cumulative counts in locomotor activity were analyzed
using Student’s t test. One-way ANOVA followed by post-hoc
Dunnett’s test was used to evaluate statistical significance compare
to saline group in EPM and FST procedures. n represents the
number of independent experiments.
Supporting Information
Data S1 Supplementary information
Found at: doi:10.1371/journal.pone.0009777.s001 (0.04 MB
DOC)
Figure S1 Cells systems for the analysis of recombinant and
neuronal TrkB receptors. (A) Representative fluorescence photo-
micrographs of TetOn-rhTrkB inducible cells following an
overnight incubation with (middle panel) or without (left panel)
doxycycline and confocal TrkB immunofluorescence in mouse
cortical neurons (right panel). Scale bar, 55 mm. (B) Western blot
analysis of TrkB expression in TetOn-rhTrkB cells treated with
increasing concentrations of doxycycline and in cultured mouse
cortical neurons. One band was detected ({similar, tilde operator }
170 kDa, closed arrowhead) for recombinant human TrkB fused
to ECFP whereas two distinct bands (95 and 145 kDa, open
arrowhead) were revealed for neuronal TrkB. Doxycycline dose-
dependently induced the expression of rhTrkB-ECFP in TetOn-
rhTrkB cells and was used at the optimal concentration of
1000 ng/ml in all further experiments. (C) Representative western
blot analysis of total and phosphorylated TrkB in TetOn-rhTrkB
cells and neurons, and total and phosphorylated MAPK and Akt
in cortical neurons, after treatment with or without BDNF (1 nM).
Found at: doi:10.1371/journal.pone.0009777.s002 (2.27 MB TIF)
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receptor using KIRA-ELISA. (A,B) KIRA-ELISA concentration-
response curves for BDNF, NT-3 and NGF in TetOn-rhTrkB cells
and in cultured cortical neurons. Results are expressed as mean 6
s.e.m. of raw absorbance read at 450 nm in six independent
experiments performed in triplicate. (C,D) Inhibition of TrkB
phosphorylation by K252a in both TetOn-rhTrkB cells and
cortical neurons. Cells were treated for 20 min with K252a prior
to treatment with (closed circle) or without (closed square) BDNF
(4 nM). K252a was dissolved in dimethyl sulphoxide (DMSO); we
verified that DMSO did not affect TrkB activity. As values
obtained with 10 mM K252a are not different from those obtained
in non-induced TetOn-rhTrkB cells (with BDNF, open circle;
without BDNF, open square; C), background signal was defined as
the value obtained with 10 mM K252a in KIRA-ELISA studies in
both cell types. Data are mean 6 s.e.m. of four experiments
performed in triplicate and results are expressed as a ratio between
phospho-TrkB and total TrkB in percentage of basal. (E) Western
blot analysis of concentration-response curve for BDNF in TetOn-
rhTrkB cells. Representative blots are shown for phospho-TrkB,
TrkB and b-Tubulin (left) as well as quantitative analysis of band
intensity (right). White and black arrows show the active form of
TrkB. Data are mean 6 s.e.m. of three experiments and results are
expressed as a ratio between phospho-TrkB and total TrkB in
percentage of basal.
Found at: doi:10.1371/journal.pone.0009777.s003 (1.05 MB
TIF)
Figure S3 Cyclotraxin-B does not compete with [
125I]-BDNF
binding to recombinant nor to neuronal TrkB receptors. Effect of
unlabeled BDNF (closed circle), NT-3 (closed triangle), NGF
(closed square), peptide L2-8 (open triangle) and cyclotraxin-B
(open circle) on [
125I]-BDNF binding to recombinant and
neuronal TrkB receptors. Adherent cells were pre-incubated
60 min at 4uC with increasing concentrations of unlabeled BDNF,
NT-3, NGF, peptide L2-8 and cyclotraxin-B before an additional
2 hours incubation at 4uC with 200 pM [
125I]-BDNF. Each point
represents the results from two independent experiments per-
formed in triplicate.
Found at: doi:10.1371/journal.pone.0009777.s004 (0.25 MB
TIF)
Figure S4 Basal activity of TrkB receptors in absence of BDNF.
(A) Absence of endogenous BDNF in cultured cortical neurons.
Neuronal cells were incubated 24 hours with a neutralizing anti-
BDNF antibody before treatment with cyclotraxin-B. KIRA-
ELISA analysis revealed no significant difference in cyclotraxin-B
inhibition with or without pretreatment with anti-BDNF. *P,0.01
compared to their respective basal condition. Data are mean 6
s.e.m. (triplicates, n=3). p.i., preincubation. (B) BDNF-indepen-
dent TrkB activity depends on TrkB density in TetOn-rhTrkB
cells. Cells were incubated overnight with increasing concentra-
tions of doxycycline. Total and phospho-TrkB were then
evaluated using fluorescence quantification and KIRA-ELISA,
respectively.
Found at: doi:10.1371/journal.pone.0009777.s005 (0.26 MB TIF)
Figure S5 BDNF-induced neuronal necrosis is prevented by
cyclotraxin-B. Cyclotraxin-B prevents BDNF-induced neurons
death through a NMDA-independent pathway. Cortical neurons
were treated with cyclotraxin-B (200 nM), BDNF (4 nM), NMDA
(200 mM) or MK-801 (1 mM), as indicated. Data are mean 6
s.e.m. (octuples, n=6) expressed in percentage of control.
***P,0.001 compared to control; $$$P,0.001, compared to
BDNF; n.s, non significant.
Found at: doi:10.1371/journal.pone.0009777.s006 (0.30 MB
TIF)
Figure S6 Cyclotraxin-B inhibits eIF4E phosphorylation in
cortical neurons. Cortical neurons were exposed to cyclotraxin-
B, K252a and BDNF, as indicated. Phosphorylation of eIF4E was
quantified by immunoblots using anti-phospho and anti-total-
eIF4E antibodies. A representative western-blot is shown here.
Found at: doi:10.1371/journal.pone.0009777.s007 (0.33 MB TIF)
Figure S7 Tat-cyclotraxin-B inhibits both recombinant and
neuronal TrkB receptors similarly to cyclotraxin-B. Characteriza-
tion of TrkB inhibition by tat-cyclotraxin-B using KIRA-ELISA
assays in TetOn-rhTrkB cells and in cortical neurons. Increasing
concentrations of tat-empty and tat-cyclotraxin-B were added to
the cells for 30 min prior to treatment with or without 4 nM
BDNF for 20 min (tat-cyclotraxin-B, closed circle; tat-cyclotraxin-
B + BDNF, open circle; tat-empty, closed triangle; tat-empty +
BDNF, open triangle). Data are mean 6 s.e.m. (triplicates, n=4,
TetOn-rhTrkB; n=2, cortical neurons).
Found at: doi:10.1371/journal.pone.0009777.s008 (0.24 MB
TIF)
Figure S8 Protocol for in vivo KIRA-ELISA analysis after
intravenous injection. (A) Adult mice received two i.v. injections
of saline buffer, tat-empty or tat-cyclotraxin-B (1). Brains were then
sliced at three levels (bregma 0.90 mm: caudate putamen/nucleus
accumbens level; bregma 21.60 mm: dorsal hippocampus level;
bregma 22.70 mm: ventral hippocampus level) and each half-slice
was treated with BDNF (4 nM) and either tat-empty or tat-
cyclotraxin-B (1 mM) (2). Slices were then solubilized and subjected
to KIRA-ELISA analyzes (3). (B) Western blot analysis of tat-
cyclotraxin-B effect on TrkB activation in vivo. Concentration-
response curve for BDNF in TetOn-rhTrkB cells. Representative
western blots of brain phospho-TrkB, total-TrkB and b-Tubulin
from mice injected with either tat-empty or tat-cyclotraxin-B are
shown (up). White and black arrows show the active form of TrkB.
Bands intensity have been quantified (down) Data are mean 6
s.e.m. (duplicates, n=6 mice/group) expressed in percentage of
control. ***P,0.001 compared to control.
Found at: doi:10.1371/journal.pone.0009777.s009 (0.95 MB TIF)
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